Navigation Links
Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents

tivity and impulsivity in children aged 6 to 17 years previously diagnosed with ADHD, as measured by several standardized tests when compared to placebo treatment.

In the two short-term trials, the primary endpoint was a reduction in ADHD symptoms as measured by the ADHD Rating Scale (ADHD-RS-IV). ADHD-RS-IV is a standardized, validated test for assessing symptoms of ADHD in children and for assessing their response to treatment. This scale, which contains 18 items, is based on the ADHD diagnostic criteria as defined in the APA's Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision(R).

In the first trial, 301, investigators compared 2 mg, 3 mg or 4 mg GXR doses to placebo during an eight-week treatment period. The participants randomized to GXR all began at the 1 mg dose. At weekly visits, doses were titrated in 1 mg increments over the first four weeks to achieve the randomized dose. Then, doses were tapered down weekly so that all participants randomized to GXR received the 1 mg dose at week eight.

Participants achieved overall significant mean reductions from baseline in ADHD-RS-IV total scores by study end, -16.7 points vs. -8.9 for placebo (P <.0001). Investigators observed improvement in ADHD-RS-IV scores as early as two weeks after dosing began, with significant improvement in all GXR dose groups occurring at the third week.

Effect sizes, calculated using results from the ADHD-RS-IV scores and evaluated using weight-adjusted actual doses, were 0.44 (0.01 to 0.04 mg/kg), 0.58 (0.05 to 0.08 mg/kg), 1.19 (0.09 to 0.12 mg/kg), and 1.34 (0.13 to 0.17 mg/kg). In general, effect sizes are categorized as small (0.2), medium (0.5) and large (0.8).

In the second short-term trial, 304, investigators examined 1 mg, 2 mg, 3 mg and 4 mg doses and placebo during nine weeks of treatment. During the first three weeks, patients started at 1 mg with doses escalating in once- weekly 1 mg increments to achieve the
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Shire to Present New Scientific Data on ADHD Treatment Portfolio at APA Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:11/22/2014)... JUNCTION, N.J. , Nov. 21, 2014 /PRNewswire/ ... company commercializing its European Union approved CytoSorb® cytokine ... worldwide, was awarded the Beacon of Light Award ... Awards Celebration.  Dr. Phillip ... "It is an honor to be recognized by ...
(Date:11/22/2014)... LONG BEACH, Calif. , Nov. 21, 2014   ... implants. Dental implants are often called the gold standard in ... teeth. They are a stable, long-lasting way to restore and ... use dental implants to replace a missing tooth or as ... to completely transform the look and feel of a smile. ...
(Date:11/22/2014)... , Nov. 21, 2014 MEDITE Group acquired ... nine months and the 3 rd quarter sales ended ... income was $448,000 for the nine months ended September 2014 ... "Even though our 3 rd quarter is usually a ... extends from July into September for many countries worldwide, we ...
Breaking Medicine Technology:CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4Long Beach Dentist, Dr. Rassouli, is Now Offering Dental Implants 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3
... 2010 The board of directors of Pfizer Inc. (NYSE: ... dividend on the company,s common stock, payable March 1, 2011, ... February 4, 2011.  Pfizer increased the dividend by approximately 11 ... (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) "This dividend increase is a ...
... Out of hundreds of Medicare Advantage ... SNP) is one of only five plans across the country that ... from the Centers for Medicare and Medicaid Services (CMS). ... and drug plans perform on a scale of one to five, ...
Cached Medicine Technology:Pfizer Declares A 20-Cent First-Quarter 2011 Dividend 2IEHP Earns Highest Rating for Medicare Part D Quality and Performance 2
(Date:11/22/2014)... 2014 “Due to my knee replacement surgery, ... Gurnee, Ill. “While using the ice grip attachment, I noticed ... there needed to be a safer way to prevent possible ... , The SPIKE BLOCK offers added safety and stability in ... to reduce injuries and damage associated with traditional spiked ice ...
(Date:11/22/2014)... Dallas, TX (PRWEB) November 22, 2014 ... Society (ICS) as the complaint that the individual ... times for voiding. The report “Nocturia – Pipeline ... therapeutic development for Nocturia, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ...
(Date:11/22/2014)... Domestic farmgate milk and dairy ... due to a fall in demand for ... amid the global financial crisis. However, these declines ... dairy manufacturers on the international scene. Strong growth ... growth, primarily due to supply constraints in some ...
(Date:11/22/2014)... 2014 Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ) ... allegedly developed Type 2 diabetes due to its use ... now underway in U.S. District Court, District of South ... the litigation will convene its next Status Conference on ... Lead Counsel for Plaintiffs and Defendants to meet and ...
(Date:11/22/2014)... Recently, UWDress.com is gratified to introduce its new ... addition, the company has also offered an attracting discount ... online supplier of wedding dresses, UWDress.com is good at ... wedding guest gowns are provided over 20 colors, which ... selection is famous for high quality. Therefore, its sales ...
Breaking Medicine News(10 mins):Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:Best Wedding Guest dresses Introduced by UWDress.com 2
... therapy changed as needed, study found , , MONDAY, May ... have only a 50-50 chance that their doctors will ... a new study finds. , Treating high blood pressure ... pressure can lead to increased risk for heart attack, ...
... Medical Center-led pilot study that showed antidepressants can significantly ... cancer patients is the focus of an article published ... the publications produced by the Journal of American Medical ... UNMCs William Lydiatt, M.D., and Bill Burke, M.D., showed ...
... new life as a stroke treatment, researchers say. , ... inhibiting white blood cells and enzymes that, at ... respectively, says Dr. David Hess, chair of the Department ... of Medicine. The broad-spectrum antibiotic also seems to reduce ...
... clinical trial led by a University of North Carolina ... an effective treatment for dysplasia in people with Barretts ... cancer. , The interim results show there is a ... placebo or sham treatment, said Dr. Nicholas Shaheen, principal ...
... International,Meeting, FAIRFAX, Va., May 19 The American ... a cancer,survivor in the Boston area who has dedicated ... the local community. The winner of the Survivor Circle ... on Tuesday, September 23,2008, at the Boston Convention and ...
... NY) Michael Brownlee, M.D., the Anita and Jack ... of Medicine of Yeshiva University, has been selected by ... prestigious David Rumbough Award for Scientific Excellence. The ... to diabetes research. Actress Dina Merrill established this ...
Cached Medicine News:Health News:Many Diabetics Don't Get Necessary Blood Pressure Treatment 2Health News:Many Diabetics Don't Get Necessary Blood Pressure Treatment 3Health News:JAMA publication features study on depression and head and neck cancer 2Health News:Old antibiotic may find new life as a stroke treatment 2Health News:Old antibiotic may find new life as a stroke treatment 3Health News:Radiofrequency ablation is effective treatment for dysplasia in Barrett's esophagus 2Health News:Award Honors Boston Cancer Survivor Who Gives Back 2Health News:Dr. Michael Brownlee receives JDRF Rumbough Award for Scientific Excellence 2
Shielding's Wrap-Around Apron is designed for front and back protection. This apron features extra wide shoulders distributing weight over a greater area to reduce fatigue....
... Apron has standard front protection. ... from the shoulders to the ... a 6" wide elastic belt. ... apron snug. Belts may be ...
Shielding's Fast Wrap Apron offers both comfort and ease of wearing. Adjustable back shoulder strap keeps apron snug. No ties or buckles....
Shielding's Standard Coat Apron with open back allows for freedom of movement, maximum flexibility and increased comfort....
Medicine Products: